The proof of concept that empagliflozin is effective in lowering glucose and sparing insulin has been recently demonstrated in a preclinical model of STZ-induced type 1 diabetes [22] but also in human studies [36], [37]. The gene discussed is INS; the disease is type 1 diabetes mellitus.